All In Biotech

Drug Trial Radar · NCT01151423

Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic Purpura

Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

75

Actual

Start

Jan 2011

Primary completion

Mar 2014

Study completion Mar 2014

Sponsor

Lead sponsor
Ablynx, a Sanofi companyIndustry
Sponsor type
Industry
First posted
Jun 28, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP. Patients received either placebo or anti-vWF Nanobody as adjunctive therapy to plasma exchange (PE).

Conditions

  • Acquired Thrombotic Thrombocytopenic Purpura

Interventions

  • CaplacizumabBiological

    * Subjects received a first intravenous (i.v.) bolus of 10 mg (filled at 5 mg/mL) caplacizumab via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session). * The first PE on study was followed by subcutaneous (s.c.) administration of 10 mg study drug within 30 minutes after the end of the PE procedure. * All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose. * Subjects received caplacizumab up to 30 days after the last PE session.

  • PlaceboBiological

    * Subjects received a first i.v. bolus of placebo via push injection within 6 hours to 15 minutes prior to the first PE on study. The first PE on study could either be the very first PE session for the current episode of aTTP (if the subject was randomized prior to the initiation of PE) or the second PE session (if the subject was randomized after a single PE session). * The first PE on study was followed by s.c. administration of placebo within 30 minutes after the end of the PE procedure. * All subsequent study drug administrations were daily s.c. injections within 30 minutes after the end of the PE procedure (if applicable) or within 24 hours of the previous dose. * Subjects received placebo up to 30 days after the last PE session.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time-to-response of Treatment Defined by a Confirmed Recovery of Platelets ≥ 150,000/µLTime frame: From the day of first study drug administration up to 30 days after first study drug administration

Locations

51 sites in 13 countries. Site status is shown where the registry gives one.

  • Investigator Site

    Los Angeles, California

  • Investigator Site

    Washington D.C., District of Columbia

  • Investigator Site

    Atlanta, Georgia

  • Investigator Site

    St Louis, Missouri

  • Investigator Site

    New York, New York

  • Investigator Site

    Rochester, New York

  • Investigator Site

    Valhalla, New York

  • Investigator Site

    Durham, North Carolina

  • Investigator Site

    Winston-Salem, North Carolina

  • Investigator Site

    Columbus, Ohio

  • Investigator Site

    Pittsburgh, Pennsylvania

  • Investigator Site

    Dallas, Texas

  • Investigator Site

    Salt Lake City, Utah

  • Investigator Site

    Liverpool, Australia

  • Investigator Site

    Melbourne, Australia

  • Investigator Site

    Woolloongabba, Australia

  • Investigator Site

    Garran, Australian Capital Territory, Australia

  • Investigator Site

    Graz, Austria

  • Investigator Site

    Vienna, Austria

  • Investigator Site

    Antwerp, Belgium

  • Investigator Site

    Brussels, Belgium

  • Investigator Site

    Leuven, Belgium

  • Investigator Site

    Namur, Belgium

  • Investigator Site

    Sofia, Bulgaria

  • Investigator Site

    Caen, France

  • Investigator Site

    Aachen, Germany

  • Investigator Site

    Berlin, Germany

  • Investigator Site

    Cologne, Germany

  • Investigator Site

    Dortmund, Germany

  • Investigator Site

    Hanover, Germany

  • Investigator Site

    Mainz, Germany

  • Investigator Site

    Mannheim, Germany

  • Investigator Site

    München, Germany

  • Investigator Site

    Ulm, Baden-Wurttemberg, Germany

  • Investigator Site

    Haifa, Israel

  • Investigator Site

    Jerusalem, Israel

  • Investigator Site

    Petah Tikva, Israel

  • Investigator Site

    Catania, Italy

  • Investigator Site

    Foggia, Italy

  • Investigator Site

    Milan, Italy

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.